NanoViricides Receives $5,000,000 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    135 Wood Street West Haven, CT 06516
  • Company Description
    NanoViricides (OTC BB: NNVC.OB) has assembled a world class team to lead us to success. We have brought together highly experienced individuals with strong expertise in their respective areas. Our team possesses the combined expertise of having performed research, development, and regulatory processing for over 25 drugs, of which 10 are approved and the rest are at various advanced clinical stages, at the team members’ previous affiliations. Our team is also highly innovative, and boasts pioneering research in varied areas that are at the fore-fronts of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes, and gene therapy.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    This new investment enables the Company to retain more than 24 months of current operating expenses as cash in hand. This strengthened financial position will allow the Company to defray certain additional testing costs for its anti-influenza drug candidate leading to an IND application, and to support the budgeted costs of certain additional equipment needed for production of the future clinical batches of its drug candidates.
  • M&A Terms
  • Venture Investor

Trending on Xconomy